All sponsors

Xenon Pharmaceuticals Inc. $XENE

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-38
RECRUITING2
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO44%

Delay Index: of 9 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.0 months). See all sponsors →

Open Xenon Pharmaceuticals Inc. on the live radar map → 📅 $XENE readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
X-TOLE
NCT03796962
P2Active, not recruitingFocal Epilepsy3252021-09-02 (+14 mo)
X-NOVA2
NCT06775379
P3Active, not recruitingMajor Depressive Disorder4502026-10 (+2 mo)
X-NOVA-OLE
NCT06922110
P3Active, not recruitingMajor Depressive Disorder4602027-01
X-ACKT
NCT05667142
P3RecruitingPrimary Generalized Tonic-Clonic Seizures1602027-04 (+22 mo)
X-NOVA3
NCT07076407
P3Active, not recruitingMajor Depressive Disorder4502027-05
XEN1101
NCT05716100
P3RecruitingFocal Onset Seizures3602028-01 (+29 mo)
X-CEED
NCT07172516
P3Active, not recruitingBipolar Disorder; Bipolar Depression4002028-06
Azetukalner
NCT07217860
P3Active, not recruitingBipolar Depression; Bipolar I Disorder4002029-06
X-TOLE4
NCT05718817
P3Enrolling by invitationFocal Epilepsy; Tonic-Clonic Seizures8802033-04 (+82 mo)